CPC214

CPC214 is a preclinical-stage small molecule therapeutic being developed by Alephoson for the treatment of non-infectious uveitis (NIU), including both anterior and posterior forms. The drug utilizes Alephoson's proprietary Cell-Penetrating Complex (CPC) technology, which is a peptide-based delivery system designed to transport therapeutic payloads across biological barriers, such as the blood-retinal barrier. This technology aims to enable effective delivery of the small molecule to the target tissues in the eye, potentially allowing for non-invasive administration while maintaining high bioavailability in the posterior segment. As of current reports, the specific molecular target of the small molecule payload in CPC214 has not been disclosed.